Investigation of beta-carotene and Lutein Transport in Caco-2 Cells: Carotenoid-carotenoid Interactions and Transport Inhibition by Ezetimibe

Typeset version

 

TY  - JOUR
  - O'Sullivan, L,Aherne, SA,O'Brien, NM
  - 2009
  - September
  - International Journal For Vitamin and Nutrition Research
  - Investigation of beta-carotene and Lutein Transport in Caco-2 Cells: Carotenoid-carotenoid Interactions and Transport Inhibition by Ezetimibe
  - Validated
  - ()
  - Bioavailability beta-carotene carotenoid interactions Caco-2 cells ezetimibe lutein transport INTESTINAL CHOLESTEROL ABSORPTION B TYPE-I XANTHOPHYLL CAROTENOIDS GREEN VEGETABLES SR-BI NPC1L1 SECRETION LYCOPENE NIEMANN-PICK-C1-LIKE-1 BIOAVAILABILITY
  - 79
  - 337
  - 347
  - Carotenoid bioavailability is influenced by a number of factors including the presence of other carotenoids, which may enhance or inhibit the transport of one another by intestinal cells. Therefore, the objectives of the present study were: first, to determine carotenoid uptake and secretion (i.e. transport) by supplementing differentiated Caco-2 cells with increasing concentrations of either lutein or beta-carotene (0-1 mu M.); second, to assess any interactions between beta-carotene and lutein on their cellular uptake and secretion; and third, to a minor extent, to determine the effects of a carotenoid absorption inhibitor, ezetimibe, on beta-carotene and lutein transport. The carotenoid mixes were used at molar ratios of 1:1 and 4:1. At equimolar concentrations, lutein had a negative impact on beta-carotene transport and vice versa. However, these effects were not seen when the ratios were adjusted to 4:1. Following treatment with ezetimibe (25-100 mu M) for 16 hours there was a reduction in beta-carotene transport, whereas a non-significant reduction in lutein transport was observed. In conclusion, this study confirmed that beta-carotene and lutein interact during their absorption, depending on the concentration/ratios used, and that carotenoid absorption is partially affected by ezetimibe.
  - DOI 10.1024/0300-9831.79.5.337
DA  - 2009/09
ER  - 
@article{V70046795,
   = {O'Sullivan,  L and Aherne,  SA and O'Brien,  NM },
   = {2009},
   = {September},
   = {International Journal For Vitamin and Nutrition Research},
   = {Investigation of beta-carotene and Lutein Transport in Caco-2 Cells: Carotenoid-carotenoid Interactions and Transport Inhibition by Ezetimibe},
   = {Validated},
   = {()},
   = {Bioavailability beta-carotene carotenoid interactions Caco-2 cells ezetimibe lutein transport INTESTINAL CHOLESTEROL ABSORPTION B TYPE-I XANTHOPHYLL CAROTENOIDS GREEN VEGETABLES SR-BI NPC1L1 SECRETION LYCOPENE NIEMANN-PICK-C1-LIKE-1 BIOAVAILABILITY},
   = {79},
  pages = {337--347},
   = {{Carotenoid bioavailability is influenced by a number of factors including the presence of other carotenoids, which may enhance or inhibit the transport of one another by intestinal cells. Therefore, the objectives of the present study were: first, to determine carotenoid uptake and secretion (i.e. transport) by supplementing differentiated Caco-2 cells with increasing concentrations of either lutein or beta-carotene (0-1 mu M.); second, to assess any interactions between beta-carotene and lutein on their cellular uptake and secretion; and third, to a minor extent, to determine the effects of a carotenoid absorption inhibitor, ezetimibe, on beta-carotene and lutein transport. The carotenoid mixes were used at molar ratios of 1:1 and 4:1. At equimolar concentrations, lutein had a negative impact on beta-carotene transport and vice versa. However, these effects were not seen when the ratios were adjusted to 4:1. Following treatment with ezetimibe (25-100 mu M) for 16 hours there was a reduction in beta-carotene transport, whereas a non-significant reduction in lutein transport was observed. In conclusion, this study confirmed that beta-carotene and lutein interact during their absorption, depending on the concentration/ratios used, and that carotenoid absorption is partially affected by ezetimibe.}},
   = {DOI 10.1024/0300-9831.79.5.337},
  source = {IRIS}
}
AUTHORSO'Sullivan, L,Aherne, SA,O'Brien, NM
YEAR2009
MONTHSeptember
JOURNAL_CODEInternational Journal For Vitamin and Nutrition Research
TITLEInvestigation of beta-carotene and Lutein Transport in Caco-2 Cells: Carotenoid-carotenoid Interactions and Transport Inhibition by Ezetimibe
STATUSValidated
TIMES_CITED()
SEARCH_KEYWORDBioavailability beta-carotene carotenoid interactions Caco-2 cells ezetimibe lutein transport INTESTINAL CHOLESTEROL ABSORPTION B TYPE-I XANTHOPHYLL CAROTENOIDS GREEN VEGETABLES SR-BI NPC1L1 SECRETION LYCOPENE NIEMANN-PICK-C1-LIKE-1 BIOAVAILABILITY
VOLUME79
ISSUE
START_PAGE337
END_PAGE347
ABSTRACTCarotenoid bioavailability is influenced by a number of factors including the presence of other carotenoids, which may enhance or inhibit the transport of one another by intestinal cells. Therefore, the objectives of the present study were: first, to determine carotenoid uptake and secretion (i.e. transport) by supplementing differentiated Caco-2 cells with increasing concentrations of either lutein or beta-carotene (0-1 mu M.); second, to assess any interactions between beta-carotene and lutein on their cellular uptake and secretion; and third, to a minor extent, to determine the effects of a carotenoid absorption inhibitor, ezetimibe, on beta-carotene and lutein transport. The carotenoid mixes were used at molar ratios of 1:1 and 4:1. At equimolar concentrations, lutein had a negative impact on beta-carotene transport and vice versa. However, these effects were not seen when the ratios were adjusted to 4:1. Following treatment with ezetimibe (25-100 mu M) for 16 hours there was a reduction in beta-carotene transport, whereas a non-significant reduction in lutein transport was observed. In conclusion, this study confirmed that beta-carotene and lutein interact during their absorption, depending on the concentration/ratios used, and that carotenoid absorption is partially affected by ezetimibe.
PUBLISHER_LOCATION
ISBN_ISSN
EDITION
URL
DOI_LINKDOI 10.1024/0300-9831.79.5.337
FUNDING_BODY
GRANT_DETAILS